- Home
- FLGC vs BOLT Comparison
FLGC vs BOLT Comparison
Compare FLGC & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- BOLT
- Stock Information
- Founded
- FLGC 2019
- BOLT 2015
- Country
- FLGC United States
- BOLT United States
- Employees
- FLGC N/A
- BOLT N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- FLGC Health Care
- BOLT Health Care
- Exchange
- FLGC Nasdaq
- BOLT Nasdaq
- Market Cap
- FLGC 17.3M
- BOLT 16.8M
- IPO Year
- FLGC 2021
- BOLT 2021
- Fundamental
- Price
- FLGC $0.51
- BOLT $0.40
- Analyst Decision
- FLGC Strong Buy
- BOLT Hold
- Analyst Count
- FLGC 4
- BOLT 5
- Target Price
- FLGC $5.67
- BOLT $1.13
- AVG Volume (30 Days)
- FLGC 126.2K
- BOLT 146.4K
- Earning Date
- FLGC 05-13-2025
- BOLT 05-13-2025
- Dividend Yield
- FLGC N/A
- BOLT N/A
- EPS Growth
- FLGC N/A
- BOLT N/A
- EPS
- FLGC N/A
- BOLT N/A
- Revenue
- FLGC $59,505,000.00
- BOLT $7,690,000.00
- Revenue This Year
- FLGC $4.28
- BOLT N/A
- Revenue Next Year
- FLGC N/A
- BOLT $77.45
- P/E Ratio
- FLGC N/A
- BOLT N/A
- Revenue Growth
- FLGC N/A
- BOLT N/A
- 52 Week Low
- FLGC $0.46
- BOLT $0.38
- 52 Week High
- FLGC $2.59
- BOLT $1.40
- Technical
- Relative Strength Index (RSI)
- FLGC 27.82
- BOLT 39.13
- Support Level
- FLGC $0.64
- BOLT $0.38
- Resistance Level
- FLGC $0.64
- BOLT $0.47
- Average True Range (ATR)
- FLGC 0.06
- BOLT 0.04
- MACD
- FLGC -0.01
- BOLT -0.00
- Stochastic Oscillator
- FLGC 18.85
- BOLT 13.27
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.